[1] Why Patients and Clinicians Turn to It Patients with refractory inflammatory bowel disease, slow-healing anastomoses, or NSAID-induced ulcers that have not responded to standard care sometimes seek peptide therapies
References Lancet Diabetes Endocrinology (2024) Efficacy and safety of coadministered onceweekly cagrilintide 2.4 mg with Semaglutide 2.4 mg in type 2 diabetes: phase 2 trial Lancet (2021) Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant cagrilintide with Semaglutide 2.4 mg: phase 1b trial Lancet (2021) Onceweekly cagrilintide for weight management: dosefinding phase 2 trial in overweight/obesity StatPearls (2025) Semaglutide: pharmacology, indications, and clinical use overview Cureus (2024) Semaglutide: risks and benefits review (PMC) WHO (2010) Best practices for injection and related procedures (WHO toolkit) SigmaAldrich (2016) Peptide Handling Guide: storage, reconstitution, and stability LibreTexts (2020) Intradermal and subcutaneous injections: clinical procedures CDC (2024) Vaccine administration: subcutaneous injection technique Additional Research and Background These sources provide related context and are not presented as support for a specific statement above
Enhanced ability to engage in therapeutic activities like exercise
Testing before treatment is not just a best practice it is the standard recommended by the NIH, the AAFP, and the NICE clinical guideline NG239 (2024)
It is often used in medical protocols to support soft-tissue healing, gut integrity, and joint comfort, particularly for active patients in Palm Beach who push their bodies with tennis, paddleboarding, or strength training
